FGEN
Closed
Fibrogen Inc
5.27
-0.03 (-0.57%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 5.3
Day's Range: 5.03 - 5.4182
Send
sign up or login to leave a comment!
When Written:
18.66
FibroGen Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics to treat serious unmet medical needs. The company's primary focus is on developing treatments for anemia, fibrosis, and cancer.
FibroGen was founded in 1993 and is headquartered in San Francisco, California. The company has research and development facilities in San Francisco, California, and Beijing, China. FibroGen has a diverse pipeline of product candidates in various stages of clinical development, including roxadustat, a first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that is being developed for the treatment of anemia in chronic kidney disease (CKD), myelodysplastic syndromes (MDS), and chemotherapy-induced anemia (CIA).
FibroGen also has product candidates in development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and liver cancer. The company has partnerships with several pharmaceutical companies, including AstraZeneca, Astellas Pharma, and Beijing Pharma.
FibroGen is publicly traded on the NASDAQ stock exchange under the ticker symbol "FGEN."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
FibroGen was founded in 1993 and is headquartered in San Francisco, California. The company has research and development facilities in San Francisco, California, and Beijing, China. FibroGen has a diverse pipeline of product candidates in various stages of clinical development, including roxadustat, a first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that is being developed for the treatment of anemia in chronic kidney disease (CKD), myelodysplastic syndromes (MDS), and chemotherapy-induced anemia (CIA).
FibroGen also has product candidates in development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and liver cancer. The company has partnerships with several pharmaceutical companies, including AstraZeneca, Astellas Pharma, and Beijing Pharma.
FibroGen is publicly traded on the NASDAQ stock exchange under the ticker symbol "FGEN."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!